Huons Group Grants Stock Options to Employees of Holding Company Huons Global
A Total of 82,370 New Shares Granted... Average Value of About 50 Million KRW Per Person
[Asia Economy Reporter Kim Ji-hee] Huons Group has decided to grant stock options to the executives and employees of its holding company, Huons Global.
On the 10th, Huons Global announced that its board of directors resolved to newly grant a total of 82,370 stock options to 109 executives and employees. Based on the exercise price, this amounts to approximately 5.6 billion KRW, averaging about 50 million KRW per person. The stock option exercise price is 67,700 KRW. The exercise period is from June 10, 2023, two years after the grant date, until June 9, 2026.
Earlier, on the 3rd, Huons Group had decided to grant a total of 487,487 shares to 918 executives and employees of its main operating companies, Huons and Humedix. Additionally, 546,581 shares were granted in March and April of this year to 210 executives and employees of four unlisted companies: Huons Biopharma, Hubena, Huons Nature, and Huons Medical.
Hot Picks Today
"Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- "No Matter How Much Freedom of Expression..." Man Spotted with Rising Sun Flag Tattoo at Starfield
- "Drink Three Cups of Coffee and Stay Up All Night Before the Test"... Manual of Insurance Planner Who Collected 1 Billion Won in Payouts
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
A Huons Group official stated, “This year alone, Huons Group has decided to grant stock options for a total of 1.11 million shares to 1,237 executives and employees. If stock options for employees who have joined within three months and new hires, who were not included this time, are approved at next year’s shareholders’ meeting, the total scale will increase further. This decision reflects the company’s confidence that there is a definite growth momentum across the group, including the contract manufacturing of the Russian COVID-19 vaccine ‘Sputnik V.’”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.